Last reviewed · How we verify
V-Boost
At a glance
| Generic name | V-Boost |
|---|---|
| Also known as | V-Boost Immunitor |
| Sponsor | Immunitor LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Understanding the Late Effects of Surviving a Pediatric Brain Tumor
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer (PHASE3)
- Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma (PHASE3)
- European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (PHASE2)
- Physical Literacy-based Intervention for Older Adults (NA)
- Dexamethasone/Pancreatic Clamp P&F (PHASE1)
- A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V-Boost CI brief — competitive landscape report
- V-Boost updates RSS · CI watch RSS
- Immunitor LLC portfolio CI